BR112015023190A2 - regulação de câncer com o uso de compostos e/ou dieta naturais - Google Patents

regulação de câncer com o uso de compostos e/ou dieta naturais

Info

Publication number
BR112015023190A2
BR112015023190A2 BR112015023190A BR112015023190A BR112015023190A2 BR 112015023190 A2 BR112015023190 A2 BR 112015023190A2 BR 112015023190 A BR112015023190 A BR 112015023190A BR 112015023190 A BR112015023190 A BR 112015023190A BR 112015023190 A2 BR112015023190 A2 BR 112015023190A2
Authority
BR
Brazil
Prior art keywords
diet
natural compounds
glucosinolates
epigallocatechin
curcumin
Prior art date
Application number
BR112015023190A
Other languages
English (en)
Portuguese (pt)
Inventor
Reynolds Brent
Deleyrolle Loic
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of BR112015023190A2 publication Critical patent/BR112015023190A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
BR112015023190A 2013-03-14 2014-03-12 regulação de câncer com o uso de compostos e/ou dieta naturais BR112015023190A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Publications (1)

Publication Number Publication Date
BR112015023190A2 true BR112015023190A2 (pt) 2017-07-18

Family

ID=51625178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023190A BR112015023190A2 (pt) 2013-03-14 2014-03-12 regulação de câncer com o uso de compostos e/ou dieta naturais

Country Status (9)

Country Link
US (2) US20160038456A1 (https=)
EP (1) EP2968260B1 (https=)
JP (2) JP6488276B2 (https=)
CN (2) CN105377252A (https=)
AU (3) AU2014240467B2 (https=)
BR (1) BR112015023190A2 (https=)
CA (1) CA2912518A1 (https=)
IN (1) IN2015DE09621A (https=)
WO (1) WO2014159500A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
KR20180014194A (ko) * 2015-06-26 2018-02-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 천연 화합물 및/또는 식단을 사용하는 염증의 치료 방법
CN107921133A (zh) * 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN108192866B (zh) * 2018-03-07 2021-05-11 郑州大学第一附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
EP3861992B1 (en) * 2020-02-07 2023-09-06 CannaFamily a.s. Combination therapy comprising plant derived compounds and antineoplastic compounds for treatment of hematological malignancies
JP7727286B2 (ja) * 2020-09-23 2025-08-21 アミノヴィタ エセ．エレ． 癌の代謝療法
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
CN1141092C (zh) * 2001-01-19 2004-03-10 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
WO2009051739A1 (en) 2007-10-16 2009-04-23 Johns Hopkins University Methods for protecting the skin from radiation insults
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102011008017A1 (de) 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
WO2012159085A2 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
US10960057B2 (en) 2012-07-05 2021-03-30 Nutramax Laboratories, Inc. Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
CA2904865A1 (en) 2013-03-15 2014-10-16 Nutramax Laboratories, Inc. Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions
KR102499654B1 (ko) 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
CA2910546C (en) 2013-05-14 2023-03-28 Mars, Incorporated Joint care composition
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
KR20180014194A (ko) 2015-06-26 2018-02-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 천연 화합물 및/또는 식단을 사용하는 염증의 치료 방법

Also Published As

Publication number Publication date
CA2912518A1 (en) 2014-10-02
EP2968260A1 (en) 2016-01-20
US20160038456A1 (en) 2016-02-11
US20210008024A1 (en) 2021-01-14
US11666549B2 (en) 2023-06-06
AU2014240467B2 (en) 2018-11-29
IN2015DE09621A (en) 2016-02-26
CN110420329A (zh) 2019-11-08
WO2014159500A1 (en) 2014-10-02
AU2020223647A1 (en) 2020-09-10
CN105377252A (zh) 2016-03-02
JP2016514135A (ja) 2016-05-19
JP6488276B2 (ja) 2019-03-20
EP2968260A4 (en) 2017-05-10
EP2968260B1 (en) 2020-12-16
JP2018162248A (ja) 2018-10-18
AU2019201369A1 (en) 2019-03-21
AU2014240467A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
BR112015023190A2 (pt) regulação de câncer com o uso de compostos e/ou dieta naturais
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
CL2017000240A1 (es) Compuestos activos hacia bromodominios
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
PH12017502375A1 (en) Method of treating inflammation using natural compounds and/or diet
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112015001952A2 (pt) material de perda de circulação com distribuição de tamanho de partícula grande multimodal
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112016018085A8 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112016017897A8 (pt) uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
PH12015502351A1 (en) Herbal compositions for treating pain and skin disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements